Biologix Hair Inc. Appoints Dr. Diego Castresana as VP of

Biologix Hair Inc. Appoints Dr. Diego Castresana as VP of Research
and Development, Director 
TORONTO, ONTARIO -- (Marketwire) -- 01/24/13 -- Biologix Hair Inc.
(OTCBB:TGPO) (OTCQB:TGPO) has appointed Dr. Diego Castresana to Vice
President of Research and Development and a member of the Company's
Board of Directors. In addition to today's appointments, Dr.
Castresana continues to serve as Vice President of Research and
Development for Biologix Hair Science Ltd., the wholly owned
subsidiary of Biologix Hair Inc., which controls the worldwide
Intellectual Property rights associated with the Biologix Hair
Therapy System(TM). 
Diego Castresana, MD, Ms. H.S.A., is a physician from Universidad del
Norte in Barranquilla, Colombia, having obtained his degree in 1993.
He attained a Master's degree in Health Services Administration from
Nova Southeastern University in 1999 and a certificate in Top
Management from Universidad del Norte in 2004.   
Dr. Castresana worked for Universidad del Norte as a graduate studies
professor, Director of Graduate Programs in Health Services
Administration, a hospital board member and as CEO of the university
hospital, where he led the process of transforming it from a basic
healthcare center to a state-of-the-art university hospital with
high-level complexity. In 2005 Diego Castresana moved to Cuenca,
Ecuador to work for American Hospital Management Company as CEO of
Hospital Universitario del Rio, the largest university hospital in
the south of the country. Dr. Castresana was appointed CEO when the
new facility was 45% built and directed all of the activities
oriented towards completion of two buildings, occupying 37,000 m(2 )
with state-of-the-art medical equipment and serving an area equal to
one-fourth of the country. Following this success he became a private
consultant for the healthcare sector in Barranquilla.  
Dr. Castresana stated, "Research and development at Biologix Hair
Inc. is extremely important. The work we are already doing with the
Beijing Institute of Technology to standardize our patent pending
Biologix Revive hair formula also has the potential to uncover
refinements and I look forward to learning both exciting new
information about alopecia as well as potential ways in which we can
continuously improve our already remarkably effective therapy. I am
pleased that R&D is an ongoing priority for Biologix and honored to
lead this effort as we work towards securing worldwide approvals for
the Biologix Hair Therapy System(TM)." 
About Biologix Hair Inc. and Biologix Hair Science Ltd.  
Biologix Hair Inc. (Biologix Hair), together with its wholly owned
biotechnology subsidiary, Biologix Hair Science Ltd. (TM) (BHS), is
focused on realizing the full market potential for its patent-pending
hair loss formula - Biologix Revive - and its demonstrated ability to
prevent and reverse the effects of alopecia, which plagues hundreds
of millions worldwide.  
Between mid-2004 and mid-2012, more than 30,000 pre-clinical-trial
treatments of Biologix Revive were administered to 5,000-plus
patients in South America suffering with varying degrees of alopecia,
as well as people seeking preventive treatment. The participating
treatment clinicians subjectively observed and reported that
virtually 100% of preventive care clients continued to retain their
healthy hair and an estimated 80-85% of the males and 90-plus% of the
females treated for hair regeneration experienced significant
regrowth of their own natural hair. And among alopecia areata
patients, virtually total hair regrowth was observed in 100% of the
cases. To date, no negative side effects have been reported.  
BHS is currently focused on obtaining FDA approval for its
breakthrough hair loss prevention and regeneration therapy and has
initiated a research and development program with one of the world's
leading medical research universities, the Beijing Institute of
Technology (BIT). The R&D program, expected to take approximately
twelve months to complete, is an important final step before formal
clinical trials and the FDA approval process begins.  
Additionally, on May 11, 2012, Venable LLC, the Washington-based law
firm overseeing the worldwide IP and regulatory approval processes on
behalf of BHS, filed a Patent Cooperation Treaty (PCT) application on
behalf of BHS for Biologix Revive in Geneva, Switzerland. The PCT is
an international treaty, administered by the World Intellectual
Property Organization (WIPO), to which 144 countries have as of now
contracted, including Canada and the United States.  
Biologix management is determined to be in a ready position to
capitalize on the high-margin sales potential of the Biologix Hair
Therapy System(TM), if and when FDA and other major market approvals
are forthcoming.  
As BHS advances the regulatory approval process, Biologix Hair,
together with wholly owned subsidiary companies operated by BHS, are
rapidly developing a global distribution network of licensed
clinicians and medical practitioners seeking to become Certified
Biologix Hair Therapists(TM) and secure exclusive territorial
purchasing and treatment rights for the Biologix Hair Therapy
Biologix Hair has decided not to risk creating any potential
regulatory conflicts by offering treatment outside the United States
and other major high-product-margin markets until FDA approval has
been granted. Therefore, the Biologix Hair Therapy System(TM) is not
yet available other than to the 5,000+ patients who participated in
the pre-clinical-trials conducted in South America. 
To learn more about Clinician Licensing opportunities, Click Here or
call toll free +1 855.737.0333 or +1 647.344.5900. 
This announcement is not an offer to sell any Biologix Hair Inc.
("Biologix") securities. Offers for any given security are made only
through applicable offering circulars and related documents filed
with the SEC pursuant to the Securities Act of 1933 or the Securities
Exchange Act of 1934. Certain statements contained herein and
subsequent oral statements made by and on behalf of Biologix may
contain "forward-looking statements". Such forward-looking statements
are identified by words such as "intends," "anticipates," "believes,"
"expects" and "hopes" and includes, without limitation, the
development of treatment centers and approval from regulatory
authorities. Forward-looking statements express our expectations or
predictions of future events or results. They are not guarantees and
are subject to many risks and uncertainties. There are a number of
factors beyond our control that could cause actual events or results
to be significantly different from those described in the
forward-looking statements. Any or all of our forward-looking
statements in this report or in any other public statements we make
may turn out to be wrong. We undertake no obligation to publicly
update or review any forward-looking statements, whether as a result
of new information, future developments or otherwise. In Canada,
Europe and the United States, the Biologix treatment is not approved
for use by Health Canada, EMA or the FDA. The company makes no
representations that it will receive Health Canada, EMA or FDA
Biologix Hair Inc.
Corporate Communications
Toll Free: +1 855.292.8585 or +1 902.801.7920
Press spacebar to pause and continue. Press esc to stop.